РОЗАРИО Мария (US),ШОРЕ Натали (CA),ДЖОРДЖ Шелли (US),КИФФЕР Тара Линн (US),КОЗИЛ Маргарет Джеймс (US),НИКОЛЯ Оливье (CA),ПРУЛ Луиз (CA)
申请号：
RU2012136824/15
公开号：
RU2012136824A
申请日:
2011.01.28
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method for improving the pharmacokinetics of VX-222 in a patient infected with HCV, comprising co-administering the patient VX-222 and VX-950.2. The method according to claim 1, where the concentration of VX-222 in the plasma, blood or liver of the patient is increased. The method according to claim 1, where the concentration of VX-222 in the patient's plasma is increased two to six times compared with the plasma concentration of VX-222, when administered without VX-950.4. The method according to claim 1, where the level of C (minimum) VX-222 is increased. The method of claim 1, wherein the value of C (max) VX-222 is increased. The method of claim 1, wherein the AUC VX-222 value is increased. The method of claim 1, wherein VX-222 is administered in an amount of from about 20 mg to about 2000 mg in each administration. The method of claim 7, wherein the amount of VX-222 is approximately 400 mg in each administration. The method of claim 1, wherein the VX-222 is administered twice daily. The method of claim 1, wherein the VX-950 is administered at about 750 mg three times a day. The method of claim 1, wherein the VX-950 is administered at approximately 1125 mg twice daily. The method of claim 1, further comprising administering to the patient one or more additional HCV drugs other than VX-950 and VX-222.13. The method of claim 12, wherein interferon is co-administered. The method of claim 12, wherein the interferon is pegylated interferon alpha-2a or pegylated interferon alpha-2b. The method of claim 12, wherein ribavirin is co-administered. The method of claim 1, wherein the VX-950 and VX-222 are administered together over a period of time ranging from about 8 weeks to about 24 weeks. The method of claim 16, wherein the VX-950 and VX-222 are administered together for approximately 12 weeks. A method of treating a patient infected with HCV, comprising administering to the patient VX-222 and VX-950, wherein the amount of VX-222 is from about 20 mg to about 400 mg
